[go: up one dir, main page]

AR053208A1 - Forma cristalina de un compuesto de quinolinona carboxamida - Google Patents

Forma cristalina de un compuesto de quinolinona carboxamida

Info

Publication number
AR053208A1
AR053208A1 ARP060101375A ARP060101375A AR053208A1 AR 053208 A1 AR053208 A1 AR 053208A1 AR P060101375 A ARP060101375 A AR P060101375A AR P060101375 A ARP060101375 A AR P060101375A AR 053208 A1 AR053208 A1 AR 053208A1
Authority
AR
Argentina
Prior art keywords
quinolinona
carboxamida
compound
crystal form
salt forms
Prior art date
Application number
ARP060101375A
Other languages
English (en)
Inventor
Paul R Fatheree
S Derek Turner
Adam A Goldblum
Robert Chao
Daniel Genov
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of AR053208A1 publication Critical patent/AR053208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una sal clorhidrato cristalina de {(1S,3R,5R)-8-[( R )-2-hidroxi-3-(metansulfonil-metil-amino)propil]-8-azabiciclo[3.2.1]oct-3-il}amida de ácido 1-isopropil-2-oxo-1,2-dihidroquinolin-3-carboxílico o un solvato del mismo. Composiciones farmacéuticas que comprenden dichas formas salinas cristalinas, métodos para utilizar dichas formas salinas cristalinas para tratar enfermedades asociadas con la actividad del receptor 5 HT4, y procesos utiles para preparar dichas formas salinas cristalinas.
ARP060101375A 2005-04-06 2006-04-06 Forma cristalina de un compuesto de quinolinona carboxamida AR053208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
AR053208A1 true AR053208A1 (es) 2007-04-25

Family

ID=37074104

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060101375A AR053208A1 (es) 2005-04-06 2006-04-06 Forma cristalina de un compuesto de quinolinona carboxamida
ARP170103029A AR110019A2 (es) 2005-04-06 2017-11-01 Forma cristalina de un compuesto de quinolinona-carboxamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170103029A AR110019A2 (es) 2005-04-06 2017-11-01 Forma cristalina de un compuesto de quinolinona-carboxamida

Country Status (30)

Country Link
US (4) US7728004B2 (es)
EP (1) EP1874766B1 (es)
JP (2) JP5230407B2 (es)
KR (1) KR101322873B1 (es)
CN (1) CN101151264B (es)
AR (2) AR053208A1 (es)
AT (1) ATE479682T1 (es)
AU (1) AU2006232129B2 (es)
BR (1) BRPI0610657A2 (es)
CA (1) CA2603654C (es)
CY (1) CY1111275T1 (es)
DE (1) DE602006016586D1 (es)
DK (1) DK1874766T3 (es)
EA (1) EA012115B1 (es)
ES (1) ES2350495T3 (es)
HK (1) HK1110866A1 (es)
HR (1) HRP20100629T1 (es)
IL (1) IL186023A (es)
MA (1) MA29403B1 (es)
MX (1) MX2007012438A (es)
MY (1) MY151075A (es)
NO (1) NO339699B1 (es)
NZ (1) NZ561900A (es)
PE (1) PE20061310A1 (es)
PL (1) PL1874766T3 (es)
PT (1) PT1874766E (es)
SI (1) SI1874766T1 (es)
TW (1) TWI377206B (es)
WO (1) WO2006108127A2 (es)
ZA (1) ZA200708071B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
JP5086091B2 (ja) * 2004-11-05 2012-11-28 セラヴァンス， インコーポレーテッド ５−ｈｔ４受容体アゴニスト化合物
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
SI2404919T1 (sl) 2005-11-08 2013-12-31 Vertex Pharmaceuticals Incorporated Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
EP2160188A2 (en) * 2007-05-17 2010-03-10 Theravance, Inc. Prokinetic agent for bowel preparation
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
ES2993060T3 (en) 2007-12-07 2024-12-20 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
HUE038141T2 (hu) 2009-04-13 2018-10-29 Theravance Biopharma R&D Ip Llc 5-HT4 receptor agonisták és acetilkolinészteráz inhibitorok kombinációi kognitív rendellenességek kezelésére
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
SI3068392T1 (sl) 2013-11-12 2021-07-30 Vertex Pharmaceuticals Incorporated Postopek za pripravo farmacevtskih sestavkov za zdravljenje bolezni, ki jih posreduje CFTR
SG11201912266QA (en) * 2017-07-31 2020-01-30 Theravance Biopharma R&D Ip Llc Methods of treating symptoms of gastroparesis using velusetrag
AU2023346889A1 (en) 2022-09-20 2025-02-20 Alfasigma S.P.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
CA2097815C (en) 1990-12-28 2001-04-17 Fumio Suzuki Quinoline derivative
WO1994012497A1 (en) 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
ATE461192T1 (de) 2003-11-24 2010-04-15 Pfizer Chinoloncarbonsäureverbindungen mit 5-ht4- rezeptoragonistischer wirkung
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
JP5086091B2 (ja) 2004-11-05 2012-11-28 セラヴァンス， インコーポレーテッド ５−ｈｔ４受容体アゴニスト化合物
US20060183901A1 (en) 2005-02-17 2006-08-17 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
EA013567B1 (ru) 2005-03-02 2010-06-30 Тереванс, Инк. Хинолиноновые соединения в качестве агонистов рецептора 5-ht
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
SI1874766T1 (sl) 2010-12-31
US20060229332A1 (en) 2006-10-12
BRPI0610657A2 (pt) 2010-07-13
AR110019A2 (es) 2019-02-13
JP5230407B2 (ja) 2013-07-10
JP2012153725A (ja) 2012-08-16
AU2006232129A1 (en) 2006-10-12
US9126994B2 (en) 2015-09-08
US20160095849A1 (en) 2016-04-07
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
CA2603654C (en) 2014-05-27
WO2006108127A3 (en) 2007-01-04
US20100197728A1 (en) 2010-08-05
WO2006108127A2 (en) 2006-10-12
ES2350495T3 (es) 2011-01-24
NO339699B1 (no) 2017-01-23
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
IL186023A0 (en) 2008-01-20
PE20061310A1 (es) 2007-01-23
MX2007012438A (es) 2007-12-05
EP1874766A2 (en) 2008-01-09
DE602006016586D1 (de) 2010-10-14
KR101322873B1 (ko) 2013-10-30
HRP20100629T1 (hr) 2010-12-31
NO20075574L (no) 2007-11-02
EA200702161A1 (ru) 2008-04-28
NZ561900A (en) 2010-12-24
JP2008535848A (ja) 2008-09-04
TWI377206B (en) 2012-11-21
CN101151264A (zh) 2008-03-26
CY1111275T1 (el) 2015-08-05
ZA200708071B (en) 2008-10-29
AU2006232129B2 (en) 2012-07-12
US20140256769A1 (en) 2014-09-11
HK1110866A1 (en) 2008-07-25
MA29403B1 (fr) 2008-04-01
CN101151264B (zh) 2011-07-06
MY151075A (en) 2014-03-31
ATE479682T1 (de) 2010-09-15
TW200643020A (en) 2006-12-16
PT1874766E (pt) 2010-11-30
EA012115B1 (ru) 2009-08-28
KR20070116988A (ko) 2007-12-11
CA2603654A1 (en) 2006-10-12
US7728004B2 (en) 2010-06-01
IL186023A (en) 2011-09-27
PL1874766T3 (pl) 2011-02-28

Similar Documents

Publication Publication Date Title
AR053208A1 (es) Forma cristalina de un compuesto de quinolinona carboxamida
ECSP10010008A (es) (2s,3r)-n-(2-((3-piridinil)metil)-azabiciclo[2.2.2]oct-3- il)benzofuran-2-carboxamida, formas de sal novedosas, y métodos de uso de los mismos
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BRPI0917608B8 (pt) formulação de droga oral para a redução de potencial efeito abusivo, processo para a fabricação de uma formulação de droga e seu uso
HN2001000268A (es) Formas de sal de amida de acido 3 - (4-bromo - 2, 6 - difluorobenciloxi) - 5 - [3 - (4 - pirrolidin - 1 - ilbutil) ureido] isotiazol - 4 - carboxilico y metodo de produccion.
AR109224A2 (es) Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento
BRPI0606199A2 (pt) hidrocloreto de rimonabant, processo para a preparação de um hidrocloreto de rimonabant, composição farmacêutica, forma de dosagem farmacêutica, uso de um hidrocloreto de rimonabant e método de tratamento
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
CO6460737A2 (es) N-((1r,2s,5r)-5-(tert -butilamino)-2-((s)-3-(7-tert-butilpirazolo[1.5-a][1.3.5]traizin -4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos
ECSP099602A (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
AR055741A1 (es) Sales de adicion de derivado de quinuclidina y composicion farmaceutica
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
BR112013017757A2 (pt) derivado de oxazina cristalino e seu uso como inibidor de bace
EA201270573A1 (ru) Гранулированный в расплаве цинакальцет
CO7071134A2 (es) Formas cristalinas de cloruro de hidrógeno de 1-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi)bencil)urea
CL2011001829A1 (es) 3&#39;-n-desmetil-4&#39;&#39;-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
BR112015007991A2 (pt) derivados de etinila como moduladores da atividade do receptor de mglur5
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
AR063924A1 (es) Analogos de pirazol
BRPI0913736A2 (pt) Composto, processo para a preparação do composto, composição farmacêutica e método para o tratamento de uma desordem do sistema nervoso central
AR051933A1 (es) Proceso para la preparacion de n-(3,5 dicloropirid-4-ilo)-4-difluormetoxi-8-metano sulfonamido-dibenzo[b,d] furano-1-carboxamida
DOP2015000049A (es) Composición farmacéutica recubierta que contiene regorafenib
TH156839A (th) รูปแบบที่เป็นผลึกของ 1-(3-เทอร์ท-บิวทิล-1-พี-โทลิล-1เอช-ไพราซอล-5-อิล)-3-(5-ฟลูออโร-2-(1-(2-ไฮดรอกซีเอทิล)-1เอช-อินดาซอล-5-อิลอกซี)เบนซิล)ยูเรียไฮโดรคลอไรด์

Legal Events

Date Code Title Description
FC Refusal